ARCH THERAPEUTICS, INC.: 10-Q filed 2024-08-19
What ARCH THERAPEUTICS, INC. reported in its quarterly report filed 2024-08-19 (fiscal Q3 2024): 30 published measures, 96 facts as tagged in accession 0001493152-24-033091.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-08-19
- Fiscal period
- fiscal Q3 2024
- Accession
- 0001493152-24-033091 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARCH THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 1,397,644 | USD | |
| At 2023-09-30 | 1,958,189 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -12,560,566 | USD | |
| At 2024-03-31 | -10,877,484 | USD | |
| At 2023-12-31 | -9,575,516 | USD | |
| At 2023-09-30 | -7,507,732 | USD | |
| At 2023-06-30 | -8,015,028 | USD | |
| At 2023-03-31 | -6,386,088 | USD | |
| At 2022-12-31 | -5,888,833 | USD | |
| At 2022-09-30 | -4,192,803 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -5,654,681 | USD | 91 |
| 2023-10-01 to 2024-06-30 | -9,805,472 | USD | 274 |
| 2024-01-01 to 2024-03-31 | -1,469,139 | USD | 91 |
| 2023-10-01 to 2023-12-31 | -2,681,652 | USD | 92 |
| 2023-04-01 to 2023-06-30 | -1,823,107 | USD | 91 |
| 2022-10-01 to 2023-06-30 | -4,525,640 | USD | 273 |
| 2023-01-01 to 2023-03-31 | -902,477 | USD | 90 |
| 2022-10-01 to 2022-12-31 | -1,800,056 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-10-01 to 2024-06-30 | -2,474,405 | USD | 274 |
| 2022-10-01 to 2023-06-30 | -2,147,480 | USD | 273 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 30,913 | USD | 91 |
| 2023-10-01 to 2024-06-30 | 108,646 | USD | 274 |
| 2023-04-01 to 2023-06-30 | 13,293 | USD | 91 |
| 2022-10-01 to 2023-06-30 | 36,207 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-10-01 to 2024-06-30 | 2,281,715 | USD | 274 |
| 2022-10-01 to 2023-06-30 | 1,487,082 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -72,591,083 | USD | |
| At 2023-09-30 | -62,055,609 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 4,444,364 | shares | 91 |
| 2023-10-01 to 2024-06-30 | 4,550,264 | shares | 274 |
| 2023-04-01 to 2023-06-30 | 1,279,967 | shares | 91 |
| 2022-10-01 to 2023-06-30 | 1,265,340 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 4,444,364 | shares | 91 |
| 2023-10-01 to 2024-06-30 | 4,550,264 | shares | 274 |
| 2023-04-01 to 2023-06-30 | 1,279,967 | shares | 91 |
| 2022-10-01 to 2023-06-30 | 1,265,340 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -1.44 | USD/shares | 91 |
| 2023-10-01 to 2024-06-30 | -2.32 | USD/shares | 274 |
| 2023-04-01 to 2023-06-30 | -1.42 | USD/shares | 91 |
| 2022-10-01 to 2023-06-30 | -3.58 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -1.44 | USD/shares | 91 |
| 2023-10-01 to 2024-06-30 | -2.32 | USD/shares | 274 |
| 2023-04-01 to 2023-06-30 | -1.42 | USD/shares | 91 |
| 2022-10-01 to 2023-06-30 | -3.58 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 3,014 | USD | |
| At 2023-09-30 | 4,599 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-10-01 to 2024-06-30 | 36,232 | USD | 274 |
| 2022-10-01 to 2023-06-30 | 213,809 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -1,021,476 | USD | 91 |
| 2023-10-01 to 2024-06-30 | -3,392,887 | USD | 274 |
| 2023-04-01 to 2023-06-30 | -1,014,337 | USD | 91 |
| 2022-10-01 to 2023-06-30 | -3,715,563 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 1,391,130 | USD | |
| At 2023-09-30 | 1,950,090 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 13,958,210 | USD | |
| At 2023-09-30 | 9,465,921 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 2,916,655 | USD | |
| At 2023-09-30 | 2,304,207 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 1,320,276 | USD | |
| At 2023-09-30 | 1,364,504 | USD |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 21,079 | USD | 91 |
| 2023-10-01 to 2024-06-30 | 66,240 | USD | 274 |
| 2023-04-01 to 2023-06-30 | 18,529 | USD | 91 |
| 2022-10-01 to 2023-06-30 | 54,882 | USD | 273 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 875,629 | USD | 91 |
| 2023-10-01 to 2024-06-30 | 2,870,163 | USD | 274 |
| 2023-04-01 to 2023-06-30 | 870,053 | USD | 91 |
| 2022-10-01 to 2023-06-30 | 3,225,753 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 155,681 | USD | 91 |
| 2023-10-01 to 2024-06-30 | 565,130 | USD | 274 |
| 2023-04-01 to 2023-06-30 | 139,048 | USD | 91 |
| 2022-10-01 to 2023-06-30 | 471,135 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 4,444,364 | shares | |
| At 2023-09-30 | 4,689,446 | shares |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 3,500 | USD | |
| At 2023-09-30 | 3,500 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 40,824 | USD | |
| At 2023-09-30 | 362,866 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -6,384,683 | USD | 91 |
| 2023-10-01 to 2024-06-30 | -10,535,474 | USD | 274 |
| 2023-04-01 to 2023-06-30 | -1,823,107 | USD | 91 |
| 2022-10-01 to 2023-06-30 | -4,525,640 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-10-01 to 2024-06-30 | 1,585 | USD | 274 |
| 2022-10-01 to 2023-06-30 | 1,316 | USD | 273 |
Nonoperating interest expense
Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 671,929 | USD | 91 |
| 2023-10-01 to 2024-06-30 | 2,451,309 | USD | 274 |
| 2023-04-01 to 2023-06-30 | 808,770 | USD | 91 |
| 2022-10-01 to 2023-06-30 | 1,968,274 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -4,633,205 | USD | 91 |
| 2023-10-01 to 2024-06-30 | -6,412,585 | USD | 274 |
| 2023-04-01 to 2023-06-30 | -808,770 | USD | 91 |
| 2022-10-01 to 2023-06-30 | -810,077 | USD | 273 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-10-01 to 2024-06-30 | -44,228 | USD | 274 |
| 2022-10-01 to 2023-06-30 | -31,910 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-10-01 to 2024-06-30 | 612,449 | USD | 274 |
| 2022-10-01 to 2023-06-30 | 1,143,162 | USD | 273 |
Inspect the source
- Entity
- ARCH THERAPEUTICS, INC. / CIK 0001537561
- Captured
- SEC response SHA-256
63d0e84748ee59ab7c6817be68d0a32b23d83273213bc50081bb86253a1d4cc2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001537561.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))